FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783135435> ?p ?o ?g. }

• W2783135435 endingPage "378" @default.
• W2783135435 startingPage "378" @default.
• W2783135435 abstract "Abstract [Backgrounds] Intravascular large B cell lymphoma (IVLBCL) is a rare subtype of extranodal diffuse large B-cell lymphoma (DLBCL) that features lymphoma cells lodged in lumina of small vessels. Because of the lack of mass formation, diagnosis by tumor biopsy is often difficult, and thus, cell-free DNA (cfDNA) analysis might be useful for assisting diagnosis of IVLBCL. In this study, we first aimed at investigating the prevalence of mutations in genes involved in the B-cell receptor, Toll-like receptor/interleukin-1 receptor, and nuclear factor kappa B pathways. We then evaluated the liquid biopsies for detection of hot-spot mutations by droplet digital polymerase chain reaction (ddPCR). [Patients and Methods] Twenty-seven IVLBCL patients whose archived samples were available were included in this study. The patients were diagnosed as IVLBCL from January 2005 to May 2017 in University of Tsukuba Hospital, JA Toride Medical Center, and Kameda Medical Center. The study was approved by the review board in each institution, and conducted according to the Declaration of Helsinki. Tissue-derived DNA (tdDNA) was extracted from formalin-fixed paraffin-embedded specimens and/or cryo-preserved bone marrow samples, in which the lymphoma cell infiltration had been pathologically confirmed. cfDNA was extracted from 1 ml of serum or plasma obtained prior to chemotherapy. We performed targeted sequence for 8 genes (B2M, BTG2, CARD11, CD79B, MYD88, PIM1, PRDM1, and TNFAIP3) in paired tdDNA and cfDNA from 9 IVLBCL subjects by Ion Torrent Personal Genome Machine (Thermo Fisher Scientific). MYD88 L265P (c.794T>C) mutational analysis was performed by ddPCR assays (BioRad) for 46 samples in total collected from 27 subjects. Statistical analysis was performed with EZR version 1.3.2. Paired t-test was used to compare variant allele frequencies (VAFs) in paired samples. [Results] All cases were categorized as the non-GCB by Hans classification. Random skin biopsies (RSB) and bone marrow biopsies (BMB) were performed in 21 and 27 patients. The diagnostic yield of RSB was 81.0% (17 of 21). Initial BMB detected lymphoma cells in 48.1% (13/27) patients, but repeated BMB increased successful detection up to 66.7% (18/27). tdDNA was available in 26 out of 27 subjects, and in 9 of which paired cfDNA was also available (Figure 1). In one subject, only cfDNA but not tdDNA was available. Targeted sequencing for 8 genes demonstrated at least one mutation in CD79B, MYD88, PIM1, or PRDM1 in both tdDNA and cfDNA, or only in cfDNA, in 8 of 9 subjects (Figure 2). We identified 3 missense CD79B mutations in 6 (66.7%; Y196C in 2, Y196H in 3, and L199P in 1). All MYD88 mutations were L265P, which were found in 5 of 9 (55.6%). Together, either Y196 CD79B or L265P MYD88 mutation was found in 7 of 9 (77.8%). PIM1 mutations and PRDM1 mutations were seen each in 3 (33.3%). VAFs were higher in cfDNA than in tdDNA (mean, 45.6% vs. 3.7%; P=0.0006, Figure 3). Four mutations in 3 patients were detected only in cfDNA. On the other hand, all variants detected in tdDNA were confirmed in cfDNA. ddPCR assay for the L265P MYD88 mutation with all 46 samples including tdDNA and cfDNA revealed the L265P MYD88 mutation in 24/46 (52.2%) samples from 16/27 (59.3%) IVLBCL patients. Furthermore, sequential analysis of cfDNA was performed in one of the MYD88 -mutated patients. The L265P MYD88 mutation was detected (VAF=30%) in cfDNA collected 17 weeks before the diagnosis of IVLBCL, whereas the mutation was not detected in DNA derived from the bone marrow sample that was collected at the same timing and resulted in the negative pathological finding. [Conclusion] Mutations in MYD88 and CD79B are frequent in IVLBCL . Targeted sequencing suggested that tumor cell-derived DNA is abundant in serum/plasma. Liquid biopsy to detect L265P MYD88 and Y196 CD79B may provide a powerful tool for approaching diagnosis of IVLBCL. Download : Download high-res image (117KB) Download : Download full-size image Disclosures Chiba: Nippon Shinyaku: Honoraria, Research Funding." @default.
• W2783135435 created "2018-01-26" @default.
• W2783135435 creator A5008908349 @default.
• W2783135435 creator A5010746455 @default.
• W2783135435 creator A5010836878 @default.
• W2783135435 creator A5014405945 @default.
• W2783135435 creator A5020298977 @default.
• W2783135435 creator A5025340212 @default.
• W2783135435 creator A5038270737 @default.
• W2783135435 creator A5042882487 @default.
• W2783135435 creator A5046158070 @default.
• W2783135435 creator A5054408940 @default.
• W2783135435 creator A5057971304 @default.
• W2783135435 creator A5059219075 @default.
• W2783135435 creator A5061599783 @default.
• W2783135435 creator A5064026305 @default.
• W2783135435 creator A5067804516 @default.
• W2783135435 creator A5068565363 @default.
• W2783135435 creator A5075804426 @default.
• W2783135435 creator A5078524474 @default.
• W2783135435 creator A5082957036 @default.
• W2783135435 creator A5084469370 @default.
• W2783135435 date "2017-12-07" @default.
• W2783135435 modified "2023-09-28" @default.
• W2783135435 title "Liquid Biopsy for the Identification of Intravascular Large B-Cell Lymphoma" @default.
• W2783135435 doi "https://doi.org/10.1182/blood.v130.suppl_1.378.378" @default.
• W2783135435 hasPublicationYear "2017" @default.
• W2783135435 type Work @default.
• W2783135435 sameAs 2783135435 @default.
• W2783135435 citedByCount "0" @default.
• W2783135435 crossrefType "journal-article" @default.
• W2783135435 hasAuthorship W2783135435A5008908349 @default.
• W2783135435 hasAuthorship W2783135435A5010746455 @default.
• W2783135435 hasAuthorship W2783135435A5010836878 @default.
• W2783135435 hasAuthorship W2783135435A5014405945 @default.
• W2783135435 hasAuthorship W2783135435A5020298977 @default.
• W2783135435 hasAuthorship W2783135435A5025340212 @default.
• W2783135435 hasAuthorship W2783135435A5038270737 @default.
• W2783135435 hasAuthorship W2783135435A5042882487 @default.
• W2783135435 hasAuthorship W2783135435A5046158070 @default.
• W2783135435 hasAuthorship W2783135435A5054408940 @default.
• W2783135435 hasAuthorship W2783135435A5057971304 @default.
• W2783135435 hasAuthorship W2783135435A5059219075 @default.
• W2783135435 hasAuthorship W2783135435A5061599783 @default.
• W2783135435 hasAuthorship W2783135435A5064026305 @default.
• W2783135435 hasAuthorship W2783135435A5067804516 @default.
• W2783135435 hasAuthorship W2783135435A5068565363 @default.
• W2783135435 hasAuthorship W2783135435A5075804426 @default.
• W2783135435 hasAuthorship W2783135435A5078524474 @default.
• W2783135435 hasAuthorship W2783135435A5082957036 @default.
• W2783135435 hasAuthorship W2783135435A5084469370 @default.
• W2783135435 hasConcept C104317684 @default.
• W2783135435 hasConcept C117643217 @default.
• W2783135435 hasConcept C121608353 @default.
• W2783135435 hasConcept C126322002 @default.
• W2783135435 hasConcept C142724271 @default.
• W2783135435 hasConcept C174475383 @default.
• W2783135435 hasConcept C2775934546 @default.
• W2783135435 hasConcept C2776232967 @default.
• W2783135435 hasConcept C2776256026 @default.
• W2783135435 hasConcept C2778559949 @default.
• W2783135435 hasConcept C2779060813 @default.
• W2783135435 hasConcept C2779338263 @default.
• W2783135435 hasConcept C2779529041 @default.
• W2783135435 hasConcept C2780151071 @default.
• W2783135435 hasConcept C30481170 @default.
• W2783135435 hasConcept C48126324 @default.
• W2783135435 hasConcept C49105822 @default.
• W2783135435 hasConcept C502942594 @default.
• W2783135435 hasConcept C55493867 @default.
• W2783135435 hasConcept C70905583 @default.
• W2783135435 hasConcept C71924100 @default.
• W2783135435 hasConcept C86803240 @default.
• W2783135435 hasConceptScore W2783135435C104317684 @default.
• W2783135435 hasConceptScore W2783135435C117643217 @default.
• W2783135435 hasConceptScore W2783135435C121608353 @default.
• W2783135435 hasConceptScore W2783135435C126322002 @default.
• W2783135435 hasConceptScore W2783135435C142724271 @default.
• W2783135435 hasConceptScore W2783135435C174475383 @default.
• W2783135435 hasConceptScore W2783135435C2775934546 @default.
• W2783135435 hasConceptScore W2783135435C2776232967 @default.
• W2783135435 hasConceptScore W2783135435C2776256026 @default.
• W2783135435 hasConceptScore W2783135435C2778559949 @default.
• W2783135435 hasConceptScore W2783135435C2779060813 @default.
• W2783135435 hasConceptScore W2783135435C2779338263 @default.
• W2783135435 hasConceptScore W2783135435C2779529041 @default.
• W2783135435 hasConceptScore W2783135435C2780151071 @default.
• W2783135435 hasConceptScore W2783135435C30481170 @default.
• W2783135435 hasConceptScore W2783135435C48126324 @default.
• W2783135435 hasConceptScore W2783135435C49105822 @default.
• W2783135435 hasConceptScore W2783135435C502942594 @default.
• W2783135435 hasConceptScore W2783135435C55493867 @default.
• W2783135435 hasConceptScore W2783135435C70905583 @default.
• W2783135435 hasConceptScore W2783135435C71924100 @default.
• W2783135435 hasConceptScore W2783135435C86803240 @default.
• W2783135435 hasLocation W27831354351 @default.
• W2783135435 hasOpenAccess W2783135435 @default.
• W2783135435 hasPrimaryLocation W27831354351 @default.

• next